2006 Silver 2.0turbo! on 2040-cars

Auto blog

What car brand should come back?

Congratulations, wishful thinker! You've been granted one wish by the automotive genie or wizard or leprechaun or whoever has been gifted with that magical ability. You get to pick one expired, retired or fired automotive brand and resurrect it from its heavenly peace! But which one? That's a tough decision and not one to be made lightly. As we know from car history, the landscape is littered with failed brands that just didn't have what it took to cut it in the dog-eat-dog world of vehicle design, engineering and marketing. So many to choose from! Because I am not a car historian, I'll leave it to a real expert to present a complete list of history's automotive misses from which you can choose, if you're a stickler about that sort of thing. And since I'm most familiar with post-World War II cars and brands, that's what I'm going to stick to (although Maxwell, Cord and some others could make strong arguments). So, with the parameters established, let's get started, shall we? Hudson: I admit, I really don't know a lot about Hudson, except that stock car drivers apparently did pretty well with them back in the day, and Paul Newman played one in the first Cars movie. But really, isn't that enough to warrant consideration? Frankly, I think the Paul Newman connection is reason enough. What other actor who drove race cars was cooler? James Dean? Steve McQueen? James Garner? Paul Walker? But, I digress. That's a story for another day. Plymouth: As the scion of a Dodge family (my grandfather had a Dodge truck, and my mom had not one, but two Dodge Darts – the rear-wheel-drive ones with slant sixes in them, not the other one they don't make any more), I tend to think of Plymouth as the "poor man's Dodge." But then you have to consider the many Hemi-powered muscle cars sold under the Plymouth brand, such as the Road Runner, the GTX, the Barracuda, and so on. Was there a more affordable muscle car than Plymouth? When you place it in the context of "affordable muscle," Plymouth makes a pretty strong argument for reanimation. Oldsmobile: When I was a teenager, all the cool kids had Oldsmobile Cutlasses, the downsized ones that came out in 1978. At one point, the Olds Cutlass was the hottest selling car in the land, if you can believe that. Then everybody started buying Honda Civics and Accords and Toyota Corollas and Camrys, and you know the rest. But going back farther, there's the 442 – perhaps Olds' finest hour when it came to muscle cars.

NEVS announces 200 layoffs as it says Saab restart will 'take time'

For a fleeting moment a few weeks ago, the news from Saab-owner National Electric Vehicle Sweden appeared almost positive. The company had its reorganization plan approved (a day after it was denied), and the automaker was actually showing a real, running vehicle, albeit one with a top speed of 75 miles per hour. But those tiny crumbs of potential goodness have been swept away because NEVS has announced layoffs of as many as 200 factory employees in September "due to lack of work."
Workers probably shouldn't get too eager to return to the factory either, because company's "decision to re-start production will be further delayed" by an unspecified amount of time, NEVS says in a press release. To begin assembling cars again, the company needs to find long-term funding and a new majority owner. Those seem like two very steep hurdles for the embattled automaker to clear.
Despite not producing cars since May, NEVS still claims it's negotiating with a new owner, possibly Mahindra, but according to Reuters, the Swedish company owes about 400 million kronor ($56 million) to creditors. According to its layoff announcement, getting rid of these workers is one step in the business' reorganization plan to be presented on October 8. Scroll down to read its full release.

NEVS, the company that took over Saab, gets new majority owner

Chinese real estate conglomerate Evergrande Group, a key investor behind troubled electric vehicle startup Faraday Future, has acquired a 51 percent stake in NEVS. That's the Chinese-backed Swedish electric vehicle company that purchased the assets of Saab out of bankruptcy in 2012. The investment by subsidiary Evergrande Health Industry Group was valued at the equivalent of $930 million and is expected to help NEVS develop new EVs. Evergrande said it paid the first installment of $430 million on Jan. 15, with the remainder due by the end of the month. The remaining 49 percent stake is controlled by a holding company controlled by NEVS founder Kai Johan Jiang. "It means that NEVS will get a financial (sic) strong main owner who is very interested in developing our vision about green mobility transport solutions for the future," NEVS CEO Stefan Tilk said in a statement. NEVS, short for National Electric Vehicle Sweden, owns production facilities in Trollhattan, Sweden, and Tianjin, China, with another under construction in Shanghai. In late 2017 the company launched what apparently was limited production of the 9-3 EV, an electric vehicle based — you guessed it — on the old Saab 9-3 platform. The company now says it will be built in Tianjin starting later this year, with components coming from Trollhattan. It boasts a 186-mile range, in-car WiFi and a cabin air filter for the notoriously smoggy Chinese air. It also showed a battery-electric 9-3X concept at CES Asia in 2017, which is likely to be its next model pegged for production. The South China Morning Post, citing local media reports, says two of NEVS' models meet the standards for mass production in China. This content is hosted by a third party. To view it, please update your privacy preferences. Manage Settings. Definitely the best promotional video we've ever seen. Evergrande Health first came to Faraday Future's rescue back in 2017 with a promised $2 billion investment, but the two sides later went into arbitration in Hong Kong over a dispute about money following the first infusion of $800 million, leading the automaker to cut staff and wages last year, casting the future of FF into doubt. At the end of 2018, Faraday announced it had entered into a new restructuring agreement with an Evergrande Health subsidiary that sees them end litigation and jettison the previous investment agreement, taking Evergrande's investment in the company to 32 percent.